MASLD遗传亚型分型揭示与GCKR可变剪接相关的降糖轴
该研究整合遗传与甘油三酯相关代谢组学特征,对18个已确立的MASLD相关变异进行聚类,在英国生物银行构建相互校正的分区多基因风险评分,检验其与肝脏生物标志物、肝脏结局及2型糖尿病的关联,并在台州纵向研究(TZL)中重复血糖相关发现。分区PRS呈现双向血糖轴:一个PRS降低空腹血糖和2型糖尿病风险,其余PRS则升高两者,尽管所有PRS均与更高的肝损伤标志物和不良肝脏结局相关。rs1260326(C>T)被优先定位为共享的MASLD-2型糖尿病信号及循环GKRP的主要顺式pQTL,T等位基因促进GCKR外显子15跳跃、减少全长GKRP并产生截短蛋白。
要点
- MASLD存在遗传上不同的亚型,对血糖和2型糖尿病风险的影响方向相反
- 一个分区PRS降低空腹血糖与2型糖尿病风险,其余PRS升高两者,但均与肝损伤标志物升高相关
- rs1260326 T等位基因通过促进GCKR外显子15跳跃减少全长GKRP,可能与降糖保护相关
核心结论
- MASLD包含遗传上不同的亚型,具有相反的血糖和2型糖尿病风险特征。
- 在降糖亚型中,rs1260326介导的GCKR可变剪接提供了与GKRP丰度降低和血糖保护相关的潜在机制联系。
- 这些发现支持对MASLD异质性采取更细化的观点,并可能为未来亚型特异性风险分层和预防提供依据。
研究设计与样本
- 研究整合遗传与甘油三酯相关代谢组学特征,对18个已确立的MASLD相关变异进行聚类。
- 在英国生物银行构建相互校正的分区多基因风险评分(PRS)。
- 在英国生物银行检验与肝脏生物标志物、肝脏结局及2型糖尿病的关联。
- 在独立中国队列台州纵向研究(TZL)中重复血糖相关发现。
- 使用共定位和精细定位优先候选位点,并进行等位基因特异性功能实验和结构建模。
主要发现
- 分区PRS揭示双向血糖轴:一个PRS降低空腹血糖和2型糖尿病风险,其余PRS升高两者。
- 所有PRS均与更高的肝损伤标志物和不良肝脏结局相关。
- 血糖效应的分歧在TZL中得以重复。
- 共定位和精细定位将GCKR rs1260326(C>T)优先定位为共享的MASLD-2型糖尿病信号及循环GKRP的主要顺式pQTL。
- 功能实验显示rs1260326 T等位基因促进GCKR外显子15跳跃,减少全长GKRP丰度并产生截短蛋白。
关键数值与推荐
- 共定位和精细定位优先定位GCKR rs1260326(C>T)为共享的MASLD-2型糖尿病信号和循环GKRP的主要顺式pQTL。
- 功能实验显示rs1260326 T等位基因促进GCKR外显子15跳跃,降低全长GKRP丰度并产生截短蛋白。
- 计算机结构建模提示截短GKRP异构体对葡萄糖激酶的结合亲和力可能降低,但该预测效应需实验验证。
临床怎么用
- 提示临床应认识MASLD的遗传异质性,部分亚型虽伴肝损伤标志物升高但血糖结局有利。
- rs1260326及相关GCKR可变剪接机制可能有助于未来MASLD亚型特异性风险分层与预防。
- 结构建模预测的截短GKRP与葡萄糖激酶结合亲和力降低尚需实验验证,暂不宜直接用于临床决策。
局限性
- 结构建模提示的截短GKRP对葡萄糖激酶结合亲和力降低仅为预测效应,需实验验证。
- 摘要未报告研究人群的详细构成及潜在混杂因素的控制情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a global metabolic condition with a complex relationship to type 2 diabetes. Yet human genetic studies suggest the existence of a MASLD subtype with favourable glycaemic effects, raising a clinically important question: how can hepatic steatosis coexist with improved glycaemic outcomes? We aimed to determine whether MASLD comprises genetically distinct subtypes with divergent glycaemic consequences, and to define the genetic basis of a glucose-lowering MASLD subtype. METHODS: We integrated genetic and triglyceride-related metabolomic profiles to cluster 18 established MASLD-associated variants and construct mutually adjusted partitioned polygenic risk scores (PRSs) in the UK Biobank. We tested associations with hepatic biomarkers, liver outcomes and type 2 diabetes, and replicated glycaemic findings in an independent Chinese cohort (the Taizhou Longitudinal Study [TZL]). We prioritised candidate loci using colocalisation and fine-mapping and performed allele-specific functional assays and structural modelling to investigate the underlying mechanism at the lead locus. RESULTS: Partitioned PRSs revealed bidirectional glycaemic axes: one PRS lowered fasting glucose and type 2 diabetes risk, whereas the remaining PRSs increased both, despite all associating with higher liver injury markers and adverse liver outcomes. The divergent glycaemic effects were replicated in the TZL. To pinpoint the genetic basis of the glucose-lowering axis, colocalisation and fine-mapping prioritised GCKR rs1260326 (C>T) as a shared MASLD-type 2 diabetes signal and the lead cis-pQTL for circulating glucokinase regulatory protein (GKRP). Functional experiments showed that the rs1260326 T allele promotes exon-15 skipping in GCKR, reduces the abundance of full-length GKRP and yields a truncated protein. In silico structural modelling suggested that the truncated GKRP isoform may have reduced binding affinity for glucokinase, although this predicted effect requires experimental validation. CONCLUSIONS/INTERPRETATION: MASLD comprises genetically distinct subtypes with opposing glycaemic and type 2 diabetes risk profiles. Within the glucose-lowering subtype, rs1260326-mediated alternative splicing of GCKR provides a potential mechanistic link to reduced GKRP abundance and glycaemic protection. These findings support a more granular view of MASLD heterogeneity and may inform future subtype-specific risk stratification and prevention.
引用
- Wu F, Du M, Sun D, et al. Genetic subtyping of MASLD reveals a glucose-lowering axis linked to GCKR alternative splicing. Diabetologia. 2026. PMID: 42977848. doi:10.1007/s00125-026-06916-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。